CARGO Therapeutics

That’s a wrap for #ASH24! We are grateful for the opportunity to present our first pre-clinical data presentation on CRG-023 and are encouraged by the shared excitement in its potential to help cancer patients. As we remain focused on our mission to deliver best-in-class, potentially curative cell therapies to cancer patients, we look forward to sharing more on our development progress.??

Today, we are proud and excited to have our Senior Scientist, Idit Sagiv Barfi, PhD present our tri-specific CAR T product candidate, CRG-023 at #ASH24! CRG-023 is the culmination of a two-year effort to design and develop a construct that aims to address several known causes of relapse associated with existing CAR T-cell therapies. Preclinical data are encouraging and demonstrated sustained, anti-tumor activity in mouse models. See how we are aiming to deliver multiple, therapeutically beneficial transgene “cargo” from a single vector with the potential to benefit cancer patients: https://lnkd.in/efqREbpf #CART #celltherapy

The CARGO team is headed to #ASH24 in San Diego this weekend where we’ll present our first data presentation on CRG-023, our CD19/CD20/CD22 tri-specific CAR T developed using a tri-cistronic construct and designed with the goal of providing patients with a broad range of B-cell malignancies with durable, complete responses. Tune in to our CRG-023 presentation where we will cover the product candidate’s innovative construct design and engineering, as well as encouraging preclinical data: #CART #celltherapy Learn More: bit.ly/3UD0vlS

We are pleased to announce the appointment of our Chief Financial Officer, Anup Radhakrishnan?as Chief Operating Officer and CFO. In this role, he will continue to oversee CARGO's financial and business strategy, while also providing operational leadership to drive the execution of our strategic goals across the enterprise. Congratulations, Anup! Learn more: https://bit.ly/412x1Sz #CART #celltherapy #CRGX

Today we announced our Q3 financial results and business updates, including 57 patients dosed with continued manufacturing success for our Phase 2 clinical study of firi-cel, and progress towards IND for our tri-specific, CRG-023, as well as the appointment of our CFO, Anup Radhakrishnan as COO and CFO. Learn more: https://bit.ly/412x1Sz?#CART #celltherapy #CRGX

CARGO is proud to be part of the strong blood cancer community that came together on #LightTheNight to support The Leukemia & Lymphoma Society's?life-saving research for cancer patients. Thank you to the CARGO team for raising your lanterns in San Francisco to bring light to the darkness of cancer! #CART #celltherapy #CRGX

We’re celebrating our one-year IPO anniversary! In this time, we have been focused on developing next-generation and potentially curative CAR T-cell therapies for cancer patients and we’re proud to share the progress we’ve made. Thank you to all our employees, investors, investigators and partners for your continued support and belief in our mission.?Learn more: www.cargo-tx.com #CART #celltherapy #Nasdaqlisted #CRGX

Today we announced our first abstract on CRG-023 to be presented at the @American Society of Hematology Annual Meeting in San Diego. CRG-023 is a CD19-, CD20- and CD22-targeting tri-specific, tri-cistronic CAR T product candidate designed to provide more patients with a broad range of B-cell malignancies with durable responses, resulting in a potential best-in-class CAR T-cell therapy. Encouraging preclinical data showed sustained, durable anti-B cell lymphoma activity. CRG-023 represents the next step in our mission to develop best-in-class, potentially curative CAR T-cell therapies. Read more about the abstract and poster presentation details here: https://bit.ly/3UD0vlS #ASH24 #celltherapy

With the rapidly evolving cell therapy landscape, how does CARGO adapt its CMC strategy for autologous cell therapy? Our Chief Technical Officer, Shishir Gadam, Ph.D., recently participated in a panel discussion on CMC challenges in cell therapy development at the 2024 Cell & Gene Meeting on the Mesa and Fierce Biotech Summit, as well as moderated a cell therapy development discussion at Chardan’s SPICI Symposium. Learn how CARGO is developing next-generation cell therapies to address unmet needs for patients. https://cargo-tx.com/ #CART #celltherapy

We are recognizing World Lymphoma Awareness Day and the 1 million patients around the world fighting this life-threatening cancer. The high unmet needs patients face, especially for those with large B-cell lymphoma (LBCL) (30-40% of all non-Hodgkin lymphomas) fuels CARGO’s mission to develop best-in-class, potentially curative CAR T-cell therapies designed to overcome the challenges and limitations of available CAR T-cell therapies. Learn more at CARGO-tx.com. #WLAD2024 #BloodCancerAwarnessMonth #celltherapy #CART